ATLANTA--(BUSINESS WIRE)--June 3, 2006--ImClone Systems Incorporated (NASDAQ: IMCL - News) today announced promising Phase I data on two of the Company’s fully-human, IgG1 monoclonal antibodies, IMC-1121B and IMC-11F8, at the American Society of Clinical Oncology 42nd Annual Meeting in Atlanta, GA.